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Background: Identification of breast cancer stem cells as the chemo-resistant and
tumor-initiating population represents an important milestone in approaching anticancer
therapies. Targeting this minor subpopulation of chemo- and radio-resistant stem-like
cells, termed as the cancer stem cells (CSCs) and their eradication could significantly
enhance clinical outcomes. Most of the presently administered chemotherapeutics
target the tumor bulk but are ineffective against the CSCs. We report here that diosgenin
(DG), a naturally occurring steroidal saponin, could effectively inhibit CSCs from three
breast cancer cell lines, MCF7, T47D and MDA-MB-231, by inducing apoptosis and
inhibiting the CSC associated phenotypes.
Methods: CSCs were enriched in these cells lines, characterized for CSC traits by
immunocytochemistry and flow cytometry. Proliferation and apoptosis assays were
performed in these breast CSCs in the presence of DG to obtain the inhibitory
concentration. Apoptosis was confirmed with gene expression analysis, Western
blotting and propidium iodide staining. TCF-LEF reporter assay, sFRP overexpression
and RNAi silencing studies were performed to study regulation of the Wnt pathway.
Statistical significance was evaluated by a two-sided Student’s t-test.
Results: Using the TCF-LEF reporter system, we show the effect of DG on CSCs
is predominantly through the network regulating CSC self renewal, the Wnt β-catenin
pathway. Specifically, the Wnt antagonist, the secreted frizzled related protein 4,
(sFRP4), had a defining role in the action of DG. Gain-of-function of sFRP4 in CSCs
could improve the response to DG wherein CSC mediators were inhibited, β-catenin
was down regulated and the effectors of epithelial to mesenchymal transition and
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pro-invasive markers were repressed. Conversely, the loss-of-function of sFRP4 had a
reverse effect on the CSC population which therein became enriched, their response
to DG treatment was modest, β-catenin levels increased, GSK3β expression decreased
and the expression of epithelial markers of CSC was completely abrogated.
Conclusion: These findings demonstrate the effect of DG on inhibiting the resilient
breast CSCs which could provide a benchmark for the development of DG-based
therapies in breast cancer treatment.
Keywords: breast cancer stem cells, diosgenin, Wnt antagonists, sFRP4, EMT
INTRODUCTION
Breast cancer is a leading cause of mortality in women worldwide.
Emerging data suggest that the root of the origin of tumor
is a small subset of cells, distinct from the tumor bulk cells,
designated as the cancer stem cells (CSCs). The existence of
CD44+, CD24-/low, Lin negative breast cancer stem cells (bCSC)
was first revealed by Al-Hajj et al. (2003). Identification of bCSC
within the tumors has created a paradigm shift in the focus of
cancer therapy and research. Conventional cancer therapies are
effective in debulking breast tumors but often fail to eradicate
the CSC population. This effect, along with their toxicity on
normal tissues, has favored the use of natural phytochemicals
over synthetic oncotherapeutics. Curcumin, a dietary polyphenol,
has been shown to inhibit bCSC by blocking self-renewal
(Kakarala et al., 2010) and epithelial to mesenchymal transition
(EMT) (Mukherjee et al., 2014). Similarly, piperine inhibited
bCSC self-renewal without causing toxicity to differentiated cells
(Kakarala et al., 2010). Diosgenin (DG), a steroidal saponin,
occurs in many dietary plants such as fenugreek and wild yam
and has been shown to be antitumorigenic in many tumors
including hepatocellular carcinoma (Li et al., 2010), breast cancer
(Srinivasan et al., 2009), colorectal cancer (Wang et al., 2004),
osteosarcoma (Corbiere et al., 2003) and leukemia (Liu et al.,
2005). The anti-tumorigenic effect of DG has been shown to be
mediated through the STAT pathway (Li et al., 2010), activation
of p53 and caspase 3 (Liu et al., 2005) and via the induction of
TRAIL death receptor DR5 (Lepage et al., 2011). DG is a naturally
occurring phytoestrogen extracted from a variety of roots and
tuber and is the bioactive compound of major pulses and edible
roots (Deshpande and Bhalsing, 2014). Although DG has been
demonstrated to have a tumorigenic effect across many cancers,
it has no known toxic effect on non-tumorigenic differentiated
cells. Based on the easy availability and occurrence in several
natural food sources (Huang et al., 2010), and the documented
ability to inhibit several tumors, we proposed to study the effect of
DG to inhibit the most tumorigenic population within the cancer,
namely the CSCs.
Cancer stem cells being a highly chemo-resistant population,
are not only left untouched by chemotherapeutics but the rapid
depletion of the non-CSC tumor mass enriches the cell number
of the CSCs. Specific targeting of CSCs is therefore imperative for
effective clinical outcome of the highly aggressive and metastatic
breast cancer. Although several studies have elucidated a potent
anti-tumorigenic property of DG, there have been no reports
on the potential of DG to destroy CSCs. We explored the effect
of DG on breast cancer stem-like cells from three breast cancer
lines having differential hormone receptor expression, that is
MDA-MB-231, (a triple receptor namely, estrogen receptor-ER),
progesterone receptor-PR and human epithelial growth factor
receptor2-HER2 negative cell line, T47D (PR and HER2 negative,
ER positive) and MCF7 (HER2 negative, ER/PR positive), so that
the effect of DG in different types of breast cancers could be
analyzed.
We hypothesized that the effect of DG on CSCs could be
through targeting the prominent regulatory network of breast
CSCs, the Wnt β-catenin pathway. We assessed the effect of this
pathway at various levels and found a pronounced presence of
Wnt antagonist, secreted frizzled related protein 4 (sFRP4) in
mediating DG-induced apoptosis of bCSCs, interlinking with the
expression of CSC-specific, proliferation and metastatic markers
and the EMT phenotype. Moreover, we also observed a simulated
interaction between β-catenin and DG by molecular docking.
These studies provide for the first time molecular insights into the
action of DG via the Wnt β-catenin network, which corroborates
DG as a potential therapeutic strategy for breast cancer treatment.
MATERIALS AND METHODS
Cell Culture, Proliferation and Apoptosis
Assays
Three breast cancer cell lines MDA-MB-231, T47D and MCF7
(NCCS, Pune, India) were enriched for bCSCs by growing as
mammospheres in growth factor enriched serum-free medium
(SFM) as reported previously (Bhuvanalakshmi et al., 2015) in
basal medium (DMEM/F-12 + DMEM-HG) with 100 U/mL
PenStrep, 2mM GlutaMAX, and containing 20 ng/mL each
of epidermal growth factor (EGF), basic fibroblast growth
factor (bFGF; R&D Systems), and leukemia inhibitory factor
(LIF; Chemicon). All cells were cultured at 37◦C in a humid
incubator with 5% CO2. MTT was performed as described
previously (Bhuvanalakshmi et al., 2015) using DG (Sigma–
Aldrich, St. Louis, MO, USA) at concentrations 0–500 µM.
After determining the IC50 value at 400 µM after 24 h, the
subsequent experiments were at this concentration of DG for
24 h. BrdU and caspase assays were performed as described
previously (Bhuvanalakshmi et al., 2014) with bCSCs from MDA-
MB-231 and T47D. Intercellular ROS assay was performed by
using a Fluorometric Intracellular ROS Kit (Sigma–Aldrich, St
Louis, MO, USA) following the manufacturer’s instructions.
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Immunofluorescent Staining
Immunocytochemistry was performed as described previously
(Bhuvanalakshmi et al., 2014) for identifying CSCs using CD44
marker, and β-catenin in sFRP4-overexpressed (OE) cells using
FITC labeled mouse anti-human antibodies. CD44 marker was
characterized in MDA-MB-231 CSCs, before and after DG
treatment. Expression of β-catenin was analyzed in MDA-MB-
231 cells over-expressing sFRP4, before and after DG treatment
and compared with cells containing empty plasmid.
Flow Cytometry
The percentage of CSCs expressing CD44 was determined by flow
cytometry to study the decrease of CD44 after treatment with DG.
After drug treatment, the cells were fixed and the CD44 positive
population was determined by incubation with mouse anti-
human FITC labeled antibodies against CD44 (1:100 dilution,
BD Biosciences) as described previously (Bhuvanalakshmi et al.,
2015).
qRT-PCR
These analyses were performed as described earlier (Warrier
et al., 2014) for the genes (all primers were purchased from Sigma
Aldrich) for CSC, drug resistance, Wnt, apoptosis (primer details
indicated in Table 1).
Western Blot
Western blotting was performed for β-catenin and phospho
β-catenin as previously described Bhuvanalakshmi et al. (2014).
Propidium Iodide Staining
Cancer stem cells with and without DG treatment were incubated
with 5 µg/ml propidium iodide (PI) and monitored every 4 h
to assess for PI accumulation inside nucleus. Red fluorescence
was visualized and captured by using Nikon Eclipse TE2000-
U fluorescent microscope. After 24 h, drug treated CSCs and
control CSC were subjected to flow cytometry.
TCF-LEF Reporter Assay
TCF/ LEF plasmid were transfected in MDA-MB-231 cells as per
Cignal TCF/LEF Reporter (GFP) Kit (Qiagen) protocol for 24 h
using lipofectamine 3000 (Invitrogen). After transfection, cells
were treated with TCF/LEF activator Wnt3a for 24 h. TCF /LEF
expression activation were confirmed by GFP florescence. Then
cells were treated with DG for 24 h and GFP fluorescence was
monitored using fluorescence microscopy and flow cytometry.
sFRP4 Overexpression Studies
sFRP4 gene inserted in plasmid pEGFP N1 (ClonTechIn)
was used for over-expressing sFRP4. MDA-MB-231 cells were
transfected using lipofectamine 3000 (Invitrogen) with MEM-
reduced serum media and without antibiotic for 24–48 h.
Efficacy of transfection was confirmed by GFP expression using
a fluorescence microscope and by RT-PCR analysis for sFRP4
expression. The GFP positive sFRP4 overexpressing (OE) cells
were used for further analysis.
Angiogenesis Assay
The ability of sFRP4 OE cells to form capillary tubes after
treatment with DG was investigated using an in vitro
angiogenesis assay kit (Millipore, USA) following the
manufacturer’s instructions.
Migration Assay
To study the effect of DG on sFRP4 OE cells, cell migration was
analyzed using a Transwell Migration System (BD Biosciences) as
described previously (Bhuvanalakshmi et al., 2014, 2015).
sFRP4 RNAi Synthesis
Total RNA were extracted from sFRP4 over expressed MDAMB
cells using the RNeasy Plus Mini Kit (Qiagen) and 1 µg
of RNA was reverse transcribed according to RevertAidTM
First strand cDNA synthesis Kit (Thermo Scientific) protocol.
sFRP4 double standard RNA (dsRNA) of 210 bp was prepared
using MEGAscript R© RNAi Kit (Life Technology). T7 promoter
sequence was synthesized along with sFRP4 primer containing
MDA-MB OE sFRP4 cDNA so as to obtain a sFRP4 PCR
product with T7 promoter hanging ends (primer details indicated
in Table 1). From this 1 µg was used to synthesize dsRNA
using T7 RNA polymerases as per MEGAscript RNAi Kit
(Life Technology) protocol. Synthesized dsRNAs for sFRP4 was
dissolved in nuclease free H20 and dsRNAs with respective base
pairs was confirmed by running on 1% agarose gel and this sFRP4
RNAi was used for silencing.
sFRP4 Silencing Study
MDA-MB-231 cells were transfected with 1 µg RNAi using
Lipofectamine 3000 (Invitrogen) with MEM-reduced serum
media without antibiotic for 3 days. The mRNA levels of sFRP4
silencing was analyzed through gene expression study using RT
& qRT-PCR.
In vivo CAM Assay
Chick chorioallantoic membrane (CAM) model was used to
analyze the in vivo anti-angiogenic property of DG. Embryonated
eggs of days 4–5 were procured from Veterinary College,
Bangalore, India, after approval by the Institutional Ethics
Committee. CSCs of MDA-MB-231 cells, and MCF7 cells without
or with DG treatment (400 µM of DG for 24 h), equal cell
numbers ( 2 × 106) in 100 µL of medium (1:1 of CSC medium
and Matrigel) were injected in the air sac region using a syringe
needle according to previously reported protocols (Balassiano
et al., 2001). Eggs were incubated at 99◦F for 3 days after
which the shell was removed carefully to expose the CAM
and observed for changes in the vascularization pattern. Each
treatment condition was performed in triplicates.
Statistical Analysis
Data are represented as mean and SE from experiments, each
performed in triplicate. Statistical significance was evaluated by
a two-sided Student’s t-test. A value of P < 0.05 was considered
significant.
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TABLE 1 | Primer sequences.
Genes Primers Base pair Annealing temperature ◦C
CD44 F-5′-CATCTACCCCAGCAACCCTA-3′ 271 56
R-5′-GGTTGTGTTTGCTCCACCTT-3′
CD24 F-5′-AACTAATGCCACCACCAAGG-3′ 188 55
R-5′-CCTGTTTTTCCTTGCCACAT-3′
ALDH F-5′-AAAGTCAAAGGCTTCCTGCCC-3′ 191 60
R-5′-CTCCTGGAACACAGGTGACT-3′
Ki67 F-5-CTGCTTTGGGGACTTGACG-3′ 201 62
R-5-GTCGACCCCGCTCCTTTT-3′
Cyclin D1 F-5′-AACTACCTGGACCGCTTCCT-3′ 187 61
R-5′-CCACTTGAGCTTGTTCACCA-3′
Bax F-5′-GCTGGACATTGGACTTCCTC-3′ 247 61
R-5′-TCAGCCCATCTTCTTCCAGA-3′
ABCC2 F-5′-AGAGCTGGCCCTTGTACTCA-3′ 492 60
R-5′-TGCGTTTCAAACTTGCTCAC-3′
sFRP4 F-5′-CGATCGGTGCAAGTGTAAA-3′ 180 60
R-5′-GACTTGAGTTCGAGGGATGG-3′
DKK1 F-5′-TCCGAGGAGAAATTGAGGAA-3′ 157 59
R-5′-CCTGAGGCACAGTCTGATGA-3′
β-Catenin F-5′-CGTCCACAACACTCTGGCTA-3′ 159 55
R-5′-GCCAGCACTTCACTGCAATA-3′
GSK3-β F-5′-ACTCCAGTGGCGAGAAGAAA-3′ 241 55
R-5′-TTGAGGACAGCAGTGTCAGG-3′
Twist F-5′-CAGCGCACCCAGTCGCTGAA-3′ 438 53
R-5′-CGCCCCACGCCCTGTTTCTT-3′
Snail F-5′-GAGGCGGTGGCAGACTAG-3′ 159 60
R-5′-GACACATCGGTCAGACCAG-3′
N-cadherin F-5′-CTCCTATGAGTGGAACAGGAACG-3′ 121 63
R-5′-TTGGATCAATGTCATAATCAAGTGCTGTA-3′
E-cadherin F-5′-ATTCTGATTCTGCTGCTCTTG-3′ 400 60
R-5′-AGTAGTCATAGTCCTGGTCTT-3′
GAPDH F-5′-CAGAACATCATCCCTGCATCCACT-3′ 181 61
R-5′-GTTGCTGTTGAAGTCACAGGAGAC-3′
RNAi sFRP4 F-5′-CCATTTGCACCCTGGAGTTC-3′ 201 56
R-5′-TCCACTTAACATCCTCCGGG-3′
RNAi sFRP4 T7 promotor F-5′-TAATACGACTCACTATAGGGAGA CCATTTGCACCCTGGAGTTC-3′ 246 66
R-5′-TAATACGACTCACTATAGGGAGA TCCACTTAACATCCTCCGGG-3′
RESULTS
Enrichment and Characterization of
Breast CSCs Showed a Signature
Pattern of CSC Markers
We enriched the CSC population in MCF7, MDA-MB-231
and T47D cell lines by culturing them in serum free,
growth factor enriched culture medium and obtained spheroid
colonies (Figure 1A). The resultant mammospheres were then
characterized for the CSC marker CD44 by flow cytometry and
the CSC enrichment was determined by comparing the extent
of CSC marker expression to the non-CSC monolayer culture
for all the three cell lines. MCF7, T47D and MDA-MB-231 cells
had an increase of 25, 39, 42% of CD44 expression respectively
over monolayer culture (Figure 1B). Next, we confirmed the
Frontiers in Pharmacology | www.frontiersin.org 4 March 2017 | Volume 8 | Article 124
fphar-08-00124 March 16, 2017 Time: 15:27 # 5
Bhuvanalakshmi et al. Diosgenin Inhibits Breast CSCs
FIGURE 1 | Characterization of breast CSC signature markers in spheroid cultures of MCF7, T47D and MDA-MB-231 by flow cytometry and
quantitative RT-PCR. (A) Photomicrographs of monolayer culture and spheroid cultures grown in CSC medium. (B) Flow cytometry study of CD44 positive cells in
monolayer culture and spheroid cultures. (C) Quantitative RTPCR of the mRNA expression of breast CSC markers, CD44, ALDH and CD24 of MCF7, T47D and
MDA-MB-231 cell lines grown in CSC medium. Results are the mean ± SD of three independent experiments performed in triplicates (∗p-value < 0.05,
#p-value < 0.01, n = 3).
enrichment of CSC by analyzing for the mRNA expression of not
only CD44 but also other breast CSC signature markers, CD24
and ALDH. As expected, CD44 and ALDH expression had nearly
doubled whereas the mRNA expression of CD24 had decreased
significantly in CSC culture (Figure 1C). These cells, thus verified
for their CSC properties, were used for further experiments.
Diosgenin Suppresses the Proliferation
of Breast CSCs by Inducing Apoptosis by
the Activation of Caspase 3/7 and the
Release of ROS
We next checked the effect of DG treatment on monolayer
and CSC cells. Using MTT assay, we observed that DG inhibits
monolayer cells of MDA-MB 231, T47D and MCF7 cell lines at
an IC50 concentration of 100 µM (Figure 2A). However, the
CSC enriched cells required a much higher concentration of
400 µM for 50% inhibition that further confirmed the chemo-
refractory nature of these CSC (Figure 2B). The estimated IC50
concentration of 400 µM of DG for CSCs was used for further
experiments. After confirming arrest of CSC proliferation by
BrdU (Figure 2C), we assayed the levels of ROS and caspase 3/7.
As shown in Figure 2D, DG substantially increased ROS levels
in both MDA-MB-231 and T47D CSCs. Caspase 3/7 assay also
showed that DG caused a twofold increase suggesting that DG
induces caspase-3-dependant apoptosis in bCSCs (Figure 2E).
Drug Intake Intensified and
Accumulation of Sub G0/G1 Cells
Observed after DG Treatment
The influx of PI, as observed by fluorescence microscopy
was much more intense in DG-treated T47D, MCF7 and
MDA-MB-231 CSCs, with T47D showing the highest response.
Furthermore, flow cytometry after PI labeling revealed an
accumulation of cells in the sub G0/G1 phase indicating cell cycle
arrest after DG treatment (Figure 2F).
Diosgenin Inhibits CSC-Specific
Properties of Mammosphere Formation
and CD44 and ALDH Expression
After treatment of bCSC from T47D, MCF7 and MDA-MB-
231, we assessed for mammosphere disruption, and saw a
marked decrease in the sphere size and disintegration in
all the three cell lines (Figure 3A). We next investigated
the mRNA expression of bCSC markers, CD44 and ALDH,
after DG treatment by quantitative RT-PCR. A decrease of
expression up to twofold was seen for both CD44 and ALDH
(Figure 3B). This was further confirmed by CD44-targeted
immunocytochemical staining in which the CD44 staining was
weak after DG treatment compared to the control bCSCs of
MDA-MB cells (Figure 3C). We then confirmed this data by
flow cytometry which showed about 25% decrease of CD44
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FIGURE 2 | Inhibition studies of breast CSCs by diosgenin by inhibiting proliferation, inducing apoptosis, release of ROS and cell cycle arrest. (A) MTT
assay shows the inhibition pattern of monolayer culture and CSC culture (B) of MCF7, T47D and MDA-MB-231 cell lines treated with diosgenin (DG) at various
concentrations. DG treatment inhibited proliferation as shown by BrdU assay (C), increased release of ROS (D) and elevated levels of caspase 3/7 (E). Data are
mean ± SEM. ∗p < 0.05; ∗∗p < 0.01, n = 3. (F) Increased uptake of propidium iodide and accumulation of sub G0 cells of T47D, MCF7 and MDA-MB CSCs after
DG treatment is shown by fluorescence microscopy (left panel) and flow cytometry (right panel).
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FIGURE 3 | Diosgenin retards proliferation of breast cancer cells by inhibiting CSC population. (A) Mammosphere disruption assay was performed after
treatment with DG on CSCs from MCF-7, MDA-MB-231 and T47D cell lines. (B) CD44 CSC marker was analyzed after treatment with DG for 24 h by RTPCR and
qRT-CR in these three cell lines. (C) Immunocytochemical staining and (D) flow cytometry with CD44 of CSCs from MDA-MB-231 showed a decrease in CD44
levels after DG treatment. Data are mean ± SEM. ∗∗p < 0.01, n = 3.
positive population after treatment with DG when compared to
the control (Figure 3D).
Apoptotic Effect of Diosgenin Is
Accompanied by Downregulation of
Drug Effluxers, Disruption of the Wnt-β
Catenin Pathway
We next examined the expression levels of proliferation-
associated markers, Ki67 and cyclin D1 and observed a twofold
decrease in bCSCs from T47D and MDA-MB-231 after DG
treatment (Figure 4A). Consistent with this, pro-apoptotic gene,
Bax was increased 2–2.5 fold after DG treatment (Figure 4A). As
it has been shown that chemoresistance of CSC is associated with
overexpression of drug eﬄuxers, we examined for the expression
of ABCC2 marker. There was twofold decrease in ABCC2
expression indicating an improved response to DG (Figure 4A).
Because of the prominent role of Wnt-β catenin signaling in
proliferation and in the CSC phenotype (Jang et al., 2015a,b), we
examined the expression of Wnt-β catenin pathway related genes.
There was a substantial decrease of the key activator β-catenin
and nearly threefold increase in GSK3ß which phosphorylates
and inactivates β-catenin (Figure 4B). Consistent with this
finding, there was an overexpression of Wnt antagonists, sFRP4
and Dkk (Figure 4B).
DG Targets Wnt-β Catenin Pathway as
Seen by the Inhibition of TCF-LEF
Controlled Genes and β Catenin
Expression
As we observed a role of the effectors of Wnt-β-catenin pathway
at the gene level, we investigated the impact of DG on the
promoter, the TCF-LEF regulating Wnt-β-catenin pathway, using
the TCF/LEF GFP reporter assay on MDA-MB CSCs. DG
treatment reduced GFP expressing cells to 58% after activation
with Wnt3a, whereas activation by Wnt3a alone showed 79.9% of
GFP positive cells. Addition of the Wnt antagonist sFRP4 also
reduced the GFP positive cells to 68.26%, whereas addition of
sFRP4 along with DG reduced the GFP population to 36.7%,
demonstrating that DG suppresses that Wnt-β-catenin pathway
(Figure 4C, upper panel). Fluorescence microscopy also revealed
the same trend of fewer GFP positive cells after DG treatment
and the least number GFP positive cells after DG and sFRP4
treatment (Figure 4C, lower panel). To confirm this involvement
further, we assessed whether or not β-catenin is inactivated after
DG treatment by analyzing the protein levels of active and
inactive β-catenin (phospho β-catenin). DG treatment resulted in
a marked increase in phospho β-catenin and a decrease in active
β-catenin (Figure 4D).
Overexpression of Wnt Antagonist sFRP4
Further Elevates Response of CSCs to
DG Accompanied by EMT Reversal
As our results indicated an involvement of Wnt antagonist sFRP4
in DG mediated apoptosis consistent with our earlier findings
that sFRP4 addition chemosenstitizes glioma stem cells to drugs
(Warrier et al., 2012; Bhuvanalakshmi et al., 2015), we were
interested in examining how bCSCs over expressing sFRP4 would
respond to DG. After transfecting MDA-MB-231 CSCs with
sFRP-EGFP containing plasmid, overexpression was confirmed
with the reporter EGFP expression (Figure 5A1) and sFRP4
expression (Figure 5A2). After treatment of sFRP4-OE cells with
DG, we observed OE cells were more responsive to DG and
showed a significant decrease in the expression of proliferation
markers, Ki67 and CyclinD1 compared to treatment with DG
alone (Figure 5B). There was a threefold down-regulation, in
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FIGURE 4 | Downregulation of drug transporters, pro-proliferation markers, upregulation of Wnt antagonists and inhibition of TCF/LEF promoter
gene by diosgenin. (A,B) Gene expression analysis of CSCs from T47D and MDA-MB-231 was done by qRT-PCR of pro-proliferation genes, CyclinD1 and Ki67,
apoptotic marker Bax, drug effluxer ABCC2, Wnt antagonists sFRP4, Dkk1, Wnt activator β-catenin and GSK3β kinase. Results are the mean ± SD of three
independent experiments performed in triplicates (∗p-value < 0.05, ∗∗p-value < 0.01, n = 3). (C) Transfection of MDA-MB with TCF-LEF promoter showed the
expression of GFP reporter regulated by TCF/LEF promoter without Wnt3a stimulation (1), after addition of only Wnt3a (2), Wnt3a and sFRP4 (3), Wnt3a and DG (4),
Wnt3a, sFRP4 and DG (5). (D) Western blotting revealed increase in phospho β-catenin and decreased β-catenin in DG treated MDA-MB CSCs.
DG treated OE cells, of pro-invasive genes, Twist and Snail and
upregulation of E-cadherin and reduction of the EMT marker
N-cadherin, which was more pronounced in OE cells treated with
DG (Figure 5B). A similar trend was seen with respect to the CSC
markers CD44 and ALDH, with DG treated OE cells showing
a more prominent reduction. Expectedly β-catenin expression
was also downregulated in DG treated OE cells (Figure 5B). It
appears that sFRP4 overexpression has sensitized bCSCs to be
more susceptible to DG treatment by abrogating pro-invasive
and EMT genes which are largely regulated by the Wnt-β-catenin
pathway (Loh et al., 2013; Jang et al., 2015b).
sFRP4 Overexpressed Cells Had
Diminished Cell Migration and
Angiogenic Tube Formation Ability and
Lowered β-Catenin Levels after DG
Treatment
There was also a marked loss of β-catenin accumulation in OE
cells and further decrease in OE + DG cells as examined by
immunocytochemistry (Figure 5C). By performing angiogenesis
assay, we could see a disruption in ring formation in OE + DG
cells (Figure 5D). Cell migration assays revealed that migration
was impeded in OE and OE+DG cells with a drastic reduction in
OE+DG treated cells (Figure 5E). This observation is consistent
with the downregulation of the pro-invasive and metastatic genes
observed in DG treated OE cells.
RNAi of sFRP4 Reverses the Effect of
sFRP4 OE by Increasing Stemness, EMT
and Activating the Wnt-β-Catenin
Pathway
To investigate the effect of depletion of sFRP4, we used RNAi-
mediated sFRP4 knockdown in MDA-MB-231 cells and studied
if the effect of sFRP OE was reverted. We observed that whilst
sFRP4 with DG addition resulted in the maximum cell death,
surprisingly knockdown of sFRP4 induced hyperproliferation
and sFRP-KD cells had poor response to DG when compared to
sFRP-OE with DG (Figure 6A). After sFRP-KD, CSC markers
CD44, ALDH was upregulated and CD24 was downregulated
(Figure 6B). Expectedly, β-catenin levels increased and GSK3β
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FIGURE 5 | Breast cancer cells overexpressing Wnt antagonist, sFRP4, is inhibited by diosgenin by suppressing the EMT pathway, retarding cell
migration and angiogenesis. (A) Transfection of MDA-MB-231 cells with pEGFP- sFRP4 plasmid showed GFP expression (A1) and overexpression (OE) of sFRP4
(A2). (B) qRTPCR analysis of sFRP over-expressing (OE) cells with and without DG treatment for markers for proliferation, Wnt-β-catenin pathway, CSC and EMT
markers. (C) Immunohistochemistry of β-catenin of sFRP4 OE cells with and without DG treatment. (D) Endothelial tube formation assay of sFRP4 OE cells with and
without DG treatment showed a marked tube disruption in DG treated cells. (E) Cell migration assay of sFRP4 OE cells with and without DG treatment showed
reduced migration in DG treated cells. Results are the mean ± SD of three independent experiments performed in triplicates (∗p-value < 0.05, ∗∗p-value < 0.01,
n = 3).
and sFRP4 levels increased and treatment of sFRP4-KO with
DG reversed these changes so that it was comparable to the
control (Figure 6B). Unexpectedly, we observed a complete
loss of the epithelial marker E-cadherin in sFRP4-KO cells.
Decrease in E-cadherin in sFRP1 KO kidney cells has been
previously documented (Ren et al., 2013). The mesenchymal
marker N-cadherin and pro-invasive marker Twist was increased
in sFRP4-KO cells which decreased to control levels after DG
treatment (Figure 6B).
Diosgenin Inhibited Vascularization by
CSCs In vivo Using CAM Assay
The chick embryo provides a good model for the study of
tumor-induced angiogenesis (Scanlon et al., 2013). We induced
angiogenesis using CSCs of MDA-MB-231, T47D and MCF7
in day’s 4–5 chick eggs with or without treatment with DG.
As observed DG treated CSCs had disrupted vasculature, as
indicated by arrows (Figure 7B) when compared to the excessive
vasculature in untreated CSC (Figure 7A). This demonstrates the
effect of DG in reducing the tumor angiogenic potential of CSCs
in vivo.
DISCUSSION
In this work, we identified an inhibitory property of DG on
the chemorefractive CSCs which could be mediated by the
dysregulation of the Wnt-β-catenin pathway. CSCs represent
an important landmark for understanding the mechanisms
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FIGURE 6 | RNAi of sFRP4 reverses the effect of sFRP4 OE by increasing stemness, inducing EMT and activating the Wnt-β-catenin pathway.
(A) Phase contrast photomicrographs of MDA-MB-231 cells with and without DG treatment after sFRP overexpression (OE) and knockdown (RNAi). (B) Quantitative
RT-PCR of MDA-MB without and with DG treatment, with and without RNAi for proliferation markers and drug effluxer, CSC markers, effectors of the Wnt-β-catenin
pathway and EMT pathway. Error bars represent the mean ± SD of three independent experiments performed in triplicates (∗p-value < 0.05, ∗∗p-value < 0.01,
n = 3).
Frontiers in Pharmacology | www.frontiersin.org 10 March 2017 | Volume 8 | Article 124
fphar-08-00124 March 16, 2017 Time: 15:27 # 11
Bhuvanalakshmi et al. Diosgenin Inhibits Breast CSCs
FIGURE 7 | Diosgenin inhibits vascularization by CSCs in vivo using CAM assay. Angiogenic patterns on the allantoic membrane of chick after injection with
untreated CSCs of MDA-MB-231 and MCF7 (A) and DG treated CSCs of MDA-MB-231 and MCF7 (B). Arrows indicate the disrupted and weak vasculature after
injection with drug treated CSC. Images are representative of experiments performed in triplicates.
of chemoresistance and cancer relapse. Breast CSCs are
responsible for metastasis and are the seeds that mediate the
spread of the tumor. Most of the existing chemotherapeutics,
whilst disseminating the non-CSCs, enrich the chemorefractory
CSCs. Natural/dietary compounds have an obvious advantage
over synthetic chemotherapeutics by virtue of their non-
toxic propensity. The advantage of using DG is that it is a
phytoestrogen present in a variety of the plants such wild yam,
fenugreek and in medicinal plants belonging to the Dioscorea
species (Yi et al., 2014). In our study, we observed that the
defining phenotype of bCSC, namely mammosphere formation
and the expression of bCSC markers, CD44 and ALDH, were
suppressed by DG in bCSC from three different cell lines,
MDA-MB-231, T47D and MCF7, showing differential receptor
expression of ER/PR/HER2. This is the first study reporting
that DG, one of the biologically active constituent of fenugreek
seeds (Shabana et al., 2009), has a direct correlation to the
expression of stemness markers. DG has been shown to have
an anti cancer effect in many cancers, including breast cancer
(Srinivasan et al., 2009), prostate (Chen et al., 2011) and lung
(Yan et al., 2009). We observed that the normally chemo resilient
bCSCs, were specifically inhibited by DG and these DG treated
CSC failed to form robust vasculature in vivo in a CAM model.
We found that this suppression of growth was accompanied
by ROS release which corroborates a similar effect of DG seen
on HepG2 cells (Kim et al., 2012). Breast CSCs are known
to be sustained by lower concentrations of ROS (Diehn et al.,
2009) which is related to an increased expression of free radical
scavenger systems. Increased release of ROS deactivates the DNA
repair-linked effectors which are at a higher level in breast
CSCs (Blanpain et al., 2011). The inhibition of proliferation
was due to apoptosis as seen by the marked accumulation
of caspase 3/7, indicating that caspase 3 dependent apoptosis
was initiated, probably resulting in the activation of Bcl-2
family of proteins associated with intrinsic apoptosis (Boland
et al., 2013). Activation of caspase has also been demonstrated
in C3A hepatocarcinoma cells after DG treatment (Li et al.,
2010).
In this study, we observed the dysregulation of the
Wnt pathway at various levels. Wnt target gene, CycD1was
downregulated drastically and in contrast Wnt antagonist Dkk1
and sFRP4 were upregulated. Dkk being an inhibitor of the co-
receptor of LRP is an antagonist of the Wnt canonical pathway
(Bao et al., 2012). sFRP4, on the other hand, is a more versatile
inhibitor of the Wnt pathway, being able to block both Wnt
(Uren et al., 2000) and Fzd (Dufourcq et al., 2008), thereby
effectively grid locking the Wnt-Fzd interactions and blocking the
transmission of the downstream signals in the canonical pathway.
sFRP4 also plays a role in the non-canonical pathways because
of its unique ability to bind both the ligand and receptor of the
Wnt pathway. However, the mechanism of action in the non-
canonical axis is still rudimentary. We saw an upregulation of
both the antagonists after DG treatment. Antagonists of Wnt
such as small molecule inhibitor, CWP232228, which inhibits the
binding of β-catenin to the TCF promoter (Jang et al., 2015a)
or short hairpin RNAs (shRNAs) suppressing Wnt1 expression
(Jang et al., 2015b) has been used for targeting breast CSCs.
Some natural compounds for e.g., silibinin, have a natural
affinity to bind β-catenin and thereby inhibit its downstream
activity (Wu et al., 2013). Because of the complexity of action
of sFRP4 and because of our earlier observation of targeted
inhibition of glioma and head and neck CSCs by sFRP4 (Warrier
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et al., 2012, 2014; Bhuvanalakshmi et al., 2015), we decided
to investigate further a combination effect of DG with sFRP4.
Along with the upregulation of Wnt antagonists, GSK3β was
OE, suggesting that the phosphorylation and inactivation of
β-catenin was initiated. This line of thought was reinforced
by the observation of higher phospho β-catenin and lower
β-catenin proteins in DG treated bCSCs. At the nuclear level,
activated β-catenin/Tcf transcriptional activities using reporter
assays provides direct evidence for the control of Wnt- β-catenin
related genes. Thus, in our study, a confirmatory evidence of DG
affecting Wnt- β-catenin regulated machinery was emphatically
established when we observed that the Wnt target genes under
the control of the TCF/LEF promoter was suppressed after DG
treatment. In addition, sFRP4 had an additive effect with DG
in the suppression of TCF/LEF promoter suggesting that DG
indeed exerts in its effect via the Wnt-β-catenin axis. Similar effect
of the arrest of β-catenin-induced transactivation of TCF/LEF
has been reported in another widely studied anti-cancer natural
compound, curcumin, in colon cancer cells (Jaiswal et al.,
2002).
Because of a clear role of Wnt antagonism that we observed
in response to DG treatment, we studied a model of breast
CSC which was overexpressing sFRP4. Expectedly, the response
to DG in sFRP4 OE cells was more drastic wherein we could
see the reversal of the EMT. Upregulation of epithelial marker
e-cadherin was accompanied by a decrease in N-cadherin and
characteristic EMT markers, twist and snail. We have shown
previously in glioma and head and neck CSCs that sFRP4 inhibits
the mesenchymal traits and promotes not only epithelial markers
but also morphology (Warrier et al., 2014; Bhuvanalakshmi
et al., 2015). Probably loss of β-catenin levels that we observed,
contributed to attaining epithelial properties after DG treatment.
Furthermore, the migratory property was severely hampered
in these cells after DG treatment. Cell migration is a pointer
toward the metastatic nature of the tumor cells (Wan et al.,
2013). Additionally, we could also see that angiogenic ring
formation was inhibited in sFRP OE cells after subjecting to
DG treatment. These findings endorse earlier reports of sFRP4
having anti-angiogenic properties (Muley et al., 2010) and sFRP4
being able to effectively stall angiogenesis in combination with
chemotherapeutics in glioma (Bhuvanalakshmi et al., 2015) and
head and neck cancers (Warrier et al., 2014).
Conversely, we show that knockdown of sFRP4 reverses
the effect of overexpression. The impact of sFRP4 knockdown
on enhancing cellular proliferation is emphatic, implying this
Wnt antagonist probably works on pathways directly affecting
self renewal. This is line with earlier reports on sFRP1,
downregulation of which is associated with poor prognosis and
therapeutic response in breast cancers (Klopocki et al., 2004;
Veeck et al., 2006). Positive breast CSC markers, CD44 and
ALDH also concomitantly increased after sFRP4 knockdown and
decreased considerably after DG treatment but a pronounced
effect was seen in the negative CSC marker CD24 which increased
in sFRP4 knockdown cells treated with DG. CD24 has been
shown to enhance DNA damage induced apoptosis in breast
cancers (Ju et al., 2011). A similar function maybe attributed
to the overexpression of CD24 in DG treated sFRP knockdown
cells. Additionally, a clear involvement of sFRP4 after DG
treatment is further corroborated by the increase in its expression
in sFRP4 knockdown treated with DG. Expression pattern
of β-catenin was reverse of the sFRP4 OE cells suggesting a
possible link between sFRP4 and the gene expression of β-catenin
itself. Unexpectedly, sFRP4 knockdown had a pronounced effect
on the expression of E-cadherin by completely abrogating its
expression which was not restored even after DG treatment.
The role of e-cadherin in governing a CSC phenotype has not
been clearly eludicated. Recent reports indicate a correlation
between nuclear localization of β-catenin which in turn regulates
the CSC phenotype (Su et al., 2015). However, no direct
link has been established between a Wnt antagonist and
e-cadherin expression. Complete loss of E-cadherin seen in
sFRP4 knockdown cells indicates a prominent role of this Wnt
antagonist in maintaining of the epithelial trait. It is also possible
that sFRP4 acts via multiple pathways which need to be explored
further.
CONCLUSION
Taken together, our study reveals that DG, a steroidal
saponin derived from natural compounds, can destroy the
highly chemorefractory and pro-metastatic breast cancer stem
like cells at higher concentrations. DG, unlike synthetic
chemotherapeutics, has little or no toxicity on vital organs in
mice (Srinivasan et al., 2009). Further, our analysis also provides
a deeper insight into the mode of action of DG at the molecular
level. We find a strong role of the Wnt-β-catenin signaling
which is interrelated with the expression of stemness traits such
as self- renewal and drug resistance. The key traits of CSC
contributing to aggressiveness and invasion, such as the EMT
and pro-invasive markers, were abrogated by DG treatment in
the cell model overexpressing Wnt antagonist. In conclusion, DG
could be promoted as a novel therapy targeting bCSCs disabling
tumor recurrence, metastasis and relapse and improve patient
survival.
AUTHOR CONTRIBUTIONS
GB: Performing experiments, preparation of manuscript. B:
Preparation of manuscript. KR: Preparation of manuscript. APK:
Partial funding of the manuscript, preparation of manuscript.
AD: Partial funding of the work, preparation of manuscript.
GS: Experimental design, preparation of manuscript. SW:
Conceptualization of the study, Procuring funds for the study,
experimental design, preparation of manuscript.
ACKNOWLEDGMENTS
This work was supported partially supported by funding from
Curtin University grants and the Department of Biotechnology,
India (BT/PR8493/MED/31/226/2013) for SW. GB is thankful for
the TMA Pai fellowship from Manipal University, India. This
work was supported by grants from National Medical Research
Frontiers in Pharmacology | www.frontiersin.org 12 March 2017 | Volume 8 | Article 124
fphar-08-00124 March 16, 2017 Time: 15:27 # 13
Bhuvanalakshmi et al. Diosgenin Inhibits Breast CSCs
Council of Singapore, and by the NCIS Yong Siew Yoon Research
Grant through donations from the Yong Loo Lin Trust to
APK. APK was supported by the National Research Foundation
Singapore and the Singapore Ministry of Education under its
Research Centers of Excellence initiative to Cancer Science
Institute of Singapore, National University of Singapore. GS was
supported by a grant from the NUHS Basic seed grant [T1-BSRG
2015-02] and Ministry of Education Tier I grant.
REFERENCES
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., and Clarke,
M. F. (2003). Prospective identification of tumorigenic breast cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 100, 3983–3988. doi: 10.1073/pnas.05302
91100
Balassiano, T. I., Alves De Paulo, S., Henriques Silva, N., Curié Cabral, M., da
Gloria, da Costa, M.,et al. (2001). Metastatic potential of MDA435 and Hep2
cell lines in chorioallantoic membrane (CAM) model. Oncol. Rep. 8, 431–433.
Bao, J., Zheng, J. J., and Wu, D. (2012). The structural basis of DKK-mediated
inhibition of Wnt/LRP signaling. Sci. Signal. 5, e22. doi: 10.1126/scisignal.
2003028
Bhuvanalakshmi, G., Arfuso, F., Dharmarajan, A., and Warrier, S. (2014).
Multifunctional properties of chicken embryonic prenatal mesenchymal stem
cells- pluripotency, plasticity, and tumor suppression. Stem Cell Rev. 10, 856–
870. doi: 10.1007/s12015-014-9530-3
Bhuvanalakshmi, G., Arfuso, F., Millward, M., Dharmarajan, A., and Warrier, S.
(2015). Secreted frizzled-related protein 4 inhibits glioma stem-like cells
by reversing epithelial to mesenchymal transition, inducing apoptosis and
decreasing cancer stem cell properties. PLoS ONE 10:e0127517. doi: 10.1371/
journal.pone.0127517
Blanpain, C., Mohrin, M., Sotiropoulou, P. A., and Passegué, E. (2011). DNA-
damage response in tissue-specific and cancer stem cells.Cell StemCell 8, 16–29.
doi: 10.1016/j.stem.2010.12.012
Boland, K., Flanagan, L., and Prehn, J. H. (2013). Paracrine control of tissue
regeneration and cell proliferation by Caspase-3. Cell Death Dis. 11, e725.
doi: 10.1038/cddis.2013.250
Chen, P. S., Shih, Y. W., Huang, H. C., and Chemg, H. W. (2011). Diosgenin a
steroidal saponininhibits migration and invasion of human prostate cancer PC3
cells by reducingmatrix metalloproteinases expression. PLoS ONE 6:e20164.
doi: 10.1371/journal.pone.0020164
Corbiere, C., Liagre, B., Bianchi, A., Bordji, K., Dauça, M., Netter, P., et al.
(2003). Different contribution of apoptosis to the antiproliferative effects of
diosgenin and other plant steroids, hecogenin and tigogenin, on human 1547
osteosarcoma cells. Int. J. Oncol. 22, 899–905. doi: 10.3892/ijo.22.4.899
Deshpande, H. A., and Bhalsing, S. R. (2014). Plant derived novel biomedicinal:
diosgenin. Int. J. Pharmacogn. Phytochem. Res. 6, 780–784.
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., et al.
(2009). Association of reactive oxygen species levels and radioresistance in
cancer stem cells. Nature 458, 780–783. doi: 10.1038/nature07733
Dufourcq, P., Leroux, L., Ezan, J., Descamps, B., Lamaziere, J. M., Costet, P., et al.
(2008). Regulation of endothelial cell cytoskeletal reorganization by a secreted
frizzled-related protein-1 and frizzled 4- and frizzled 7-dependent pathway: role
in neovessel formation. Am. J. Pathol. 172, 37–49. doi: 10.2353/ajpath.2008.
070130
Huang, C. H., Liu, D. Z., and Jan, T. R. (2010). Diosgenin, a plant derived
sapogenin, enhances regulatory T-cell immunity in the intestine of mice with
food allergy. J. Nat. Prod. 73, 1033–1037. doi: 10.1021/np900690z
Jaiswal, A. S., Marlow, B. P., Gupta, N., and Narayan, S. (2002). Beta-catenin
mediated transactivation and cell-cell adhesion pathways are important in
curcumin (diferuylmethane) induced growth arrest and apoptosis in colon
cancer cells. Oncogene 21, 8414–8427. doi: 10.1038/sj.onc.1205947
Jang, G. B., Hong, I. S., Kim, R. J., Lee, S. Y., Park, S. J., Lee, E. S., et al. (2015a).
Wnt/β-catenin small-molecule inhibitor CWP232228 preferentially inhibits the
growth of breast cancer stem-like cells. Cancer Res. 75, 1691–1702. doi: 10.1158/
0008-5472.CAN-14-2041
Jang, G. B., Kim, J. Y., Cho, S. D., Park, K. S., Jung, J. Y., Lee, H. Y.,
et al. (2015b). Blockade of Wnt/βcatenin signaling suppresses breast cancer
metastasis by inhibiting CSC-like phenotype. Sci Rep. 5:12465. doi: 10.1038/srep
12465
Ju, J. H., Jang, K., Lee, K. M., Kim, M., Kim, J., Yi, J. Y., et al. (2011). CD24
enhances DNA damage-induced apoptosis by modulating NF-κB signaling
in CD44-expressing breastcancer cells. Carcinogenesis 32, 1474–1483. doi: 10.
1093/carcin/bgr173
Kakarala, M., Brenner, D. E., Korkaya, H., Cheng, C., Tazi, K., Ginestier, C.,
et al. (2010). Targeting breast stem cells with the cancer preventive compounds
curcumin and piperine. Breast Cancer Res. Treat. 122, 777–785. doi: 10.1007/
s10549-009-0612-x
Kim, D. S., Jeon, B. K., Lee, Y. E., Woo, W. H., and Mun, Y. J. (2012). Diosgenin
induces apoptosis in HepG2 cells through generation of reactive oxygen
species and mitochondrial pathway. Evid. Based Complement. Alternat. Med.
2012:981675. doi: 10.1155/2012/981675
Klopocki, E., Kristiansen, G., Wild, P. J., Klaman, I., Castanos-Velez, E., Singer, G.,
et al. (2004). Loss of SFRP1 is associated with breast cancer progression and
poor prognosis in early stage tumors. Int. J. Oncol. 25, 641–649. doi: 10.3892/
ijo.25.3.641
Lepage, C., Léger, D. Y., Bertrand, J., Martin, F., Beneytout, J. L., and Liagre, B.
(2011). Diosgenin induces death receptor-5 through activation of p38 pathway
and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Lett. 28,
193–202. doi: 10.1016/j.canlet.2010.12.003
Li, F., Fernandez, P. P., Rajendran, P., Hui, K. M., and Sethi, G. (2010). Diosgenin
a steroidal saponin inhibits STAT3 signaling pathway leading to suppression of
proliferation and chemosentization of human hepatocellular carcinoma cells.
Cancer Lett. 292, 197–207. doi: 10.1016/j.canlet.2009.12.003
Liu, M. J., Wang, Z., Ju, Y., Wong, R. N., and Wu, O. Y. (2005). Diosgenin
induces cell cycle arrest and apoptosis in human leukemia K562 cells with the
disruption of Ca2+ homeostasis. Cancer Chemother. Pharmacol. 55, 79–90.
doi: 10.1007/s00280-004-0849-3
Loh, Y. N., Hedditch, E. L., Baker, L. A., Jary, E., Ward, R. L., and Ford, C. E. (2013).
The Wnt signalling pathway is upregulated in an in vitro model of acquired
tamoxifen resistant breast cancer. BMCCancer 13:174. doi: 10.1186/1471-2407-
13-174
Mukherjee, S., Mazumdar, M., Chakraborty, S., Manna, A., Saha, S., Khan, P., et al.
(2014). Curcumin inhibits breast cancer stem cells migration by amplifying
the E cadherin/ β catenin negative feedback loop. Stem Cell Res. Ther. 5, 116.
doi: 10.1186/scrt506
Muley, A., Majumder, S., Kolluru, G. K., Parkinson, S., Viola, H., Hool, L., et al.
(2010). Secreted frizzled-related protein 4: an angiogenesis inhibitor. J. Pathol.
176, 1505–1516. doi: 10.2353/ajpath.2010.090465
Ren, J., Wang, R., Huang, G., Song, H., Chen, Y., and Chen, L. (2013).
sFRP1 inhibits epithelial-mesenchymal transition in A549 human lung
adenocarcinoma cell line. Cancer Biother. Radiopharm. 28, 565–571. doi: 10.
1089/cbr.2012.1453
Scanlon, C. S., Inglehart, R. C., and D’Silva, N. J. (2013). Emerging value: the
chick chorioallantoic membrane (Cam) model in oral carcinogenesis research.
J. Carcinog. Mutagen. S5:005. doi: 10.4172/2157-2518.S5-005
Shabana, S., Michelle, S., Sushant, K., Nancy, D., Michael, A., Carducci, A., et al.
(2009). Fenugreek: a naturally occurring edible spice as an anticancer agent.
Cancer Biol. Ther. 8, 272–278. doi: 10.4161/cbt.8.3.7443
Srinivasan, S., Koduru, S., Kumar, R., Venguswamy, G., Kyprianou, N., and
Damodaran, C. (2009). Diosgenin targets Akt-mediated prosurvival signaling
in human breast cancer cells. Int. J. Cancer 125, 961–967. doi: 10.1002/ijc.24419
Su, Y. J., Chang, Y. W., Lin, W. H., Liang, C. L., and Lee, J. L. (2015). An aberrant
nuclear localization of E-cadherin is a potent inhibitor of Wnt/β-catenin-
elicited promotion of thecancer stem cell phenotype. Oncogenesis 15:e157.
doi: 10.1038/oncsis.2015.17
Uren, A., Reichsman, F., Anest, V., and Taylor, W. G. (2000). Muraiso K, Bottaro
DP, et al. Secreted frizzled-related protein-1 binds directly to Wingless and
is a biphasic modulator of Wnt signaling. J. Biol. Chem. 275, 4374–4382.
doi: 10.1074/jbc.275.6.4374
Frontiers in Pharmacology | www.frontiersin.org 13 March 2017 | Volume 8 | Article 124
fphar-08-00124 March 16, 2017 Time: 15:27 # 14
Bhuvanalakshmi et al. Diosgenin Inhibits Breast CSCs
Veeck, J., Niederacher, D., An, H., Klopocki, E., Wiesmann, F., Betz, B., et al.
(2006). Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is
associated with unfavourable prognosis. Oncogene 25, 3479–3488. doi: 10.1038/
sj.onc.1209386
Wan, L., Pantel, K., and Kang, Y. (2013). Tumor metastasis: moving new biological
insights into the clinic. Nat. Med. 19, 1450–1464. doi: 10.1038/nm.3391
Wang, S. L., Cai, B., Cui, C. B., Liu, H. W., Wu, C. F., and Yao,
X. S. (2004). Diosgenin-3-O-alpha-L-rhamnopyranosyl-(1 > 4)-beta-D-
glucopyranoside obtained as a new anticancer agent from Dioscorea
futschauensis induces apoptosis on human colon carcinoma HCT-15 cells via
mitochondria-controlled apoptotic pathway. J. Asian Nat. Prod. Res. 6, 115–125.
doi: 10.1080/1028602031000147357
Warrier, S., Balu, S. K., Kumar, A. P., Millward, M., and Dharmarajan, A.
(2012). Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases
chemotherapeutic response of glioma stem-like cells. Oncol. Res. 21, 93–102.
doi: 10.3727/096504013X13786659070154
Warrier, S., Bhuvanalakshmi, G., Arfuso, F., Rajan, G., Millward, M.,
and Dharmarajan, A. (2014). Cancer stem-like cells from head and
neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by
inducing apoptosis, decreasing stemness, drug resistance and epithelial to
mesenchymal transition. Cancer Gene Ther. 21, 381–388. doi: 10.1038/cgt.
2014.42
Wu, K., Ning, Z., Zeng, J., Fan, J., Zhou, J., Zhang, T., et al. (2013). Silibinin
inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via
dual-blocking epithelial-mesenchymal transition and stemness. Cell. Signal. 25,
2625–2633. doi: 10.1016/j.cellsig.2013.08.028
Yan, L. L., Zhang, Y. J., Gao, W. Y., Man, S. L., and Wang, Y. (2009). In vitro
and in vivo anticancer activity of steroid saponins of Paris polyphylla var.
yunnanensis. Exp Oncol. 31, 27–32.
Yi, T., Fan, L. L., Chen, H. L., Zhu, G. Y., Suen, H. M., Tang, Y. N., et al. (2014).
Comparative analysis of diosgenin in Dioscorea species and related medicinal
plants by UPLC-DAD-MS. BMCBiochem. 15:19. doi: 10.1186/1471-2091-15-19
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Bhuvanalakshmi, Basappa, Rangappa, Dharmarajan, Sethi,
Kumar and Warrier. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 14 March 2017 | Volume 8 | Article 124
